Intravenous Formulation Archives

FDA Approves AbbVie’s Dalvance for Acute Skin Infections in Children

AbbVie, Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Approvals, Children, Intravenous Formulation, Methicillin-Resistant Staphylococcus Aureus (MRSA), Newborns, Pediatrics, Skin Infections, Therapeutics

The U.S. Food and Drug Administration approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections in pediatric patients as young as newborns.

Avenue Therapeutics Plunges as FDA Rejects NDA for IV Tramadol

Acute Pain, Business, Clinical Trials, Complete Response Letter, Intravenous Formulation, New Drug Application Rejection, Premarket Trading, R&D, Shares

Shares of Avenue Therapeutics plunged in trading after the company announced the U.S. Food and Drug Administration rejected the New Drug Application for intravenous tramadol over safety concerns.

Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties

Analysis, Arbitration, Blockbusters, Drug Formulations, Intravenous Formulation, Intravenous Injections, Multiple myeloma, Reuters, Royalties, Subcutaneous Formulation, Therapeutics

Genmab is squaring off with Janssen in a legal battle over royalties from the multiple myeloma drug Darzalex, and shares of the Denmark-based company fell in trading after the announcement.